KNAW

PDD Holdings Announces Second Quarter 2023 Unaudited Financial Results

Retrieved on: 
Tuesday, August 29, 2023
Royal Netherlands Academy of Arts and Sciences, Advertising, Natural science, General counsel, IST, Engineering, Marketing, ADS, Food safety, PDD, Wageningen University & Research, KNAW, US, Investment, Toxicology, Webcast, Growth, Research, Annual report, Total, Video game, Management, Cryptocurrency, Bank

DUBLIN and SHANGHAI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- PDD Holdings Inc. (“PDD Holdings” or the “Company”) (NASDAQ: PDD), today announced its unaudited financial results for the second quarter ended June 30, 2023.

Key Points: 
  • DUBLIN and SHANGHAI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- PDD Holdings Inc. (“PDD Holdings” or the “Company”) (NASDAQ: PDD), today announced its unaudited financial results for the second quarter ended June 30, 2023.
  • Total revenues in the quarter were RMB52,280.7 million (US$17,209.8 million), an increase of 66% from RMB31,439.6 million in the same quarter of 2022.
  • Operating profit in the quarter was RMB12,718.8 million (US$1,754.0 million), an increase of 46% from RMB8,697.2 million in the same quarter of 2022.
  • Non-GAAP2 operating profit in the quarter was RMB14,609.4 million (US$2,014.7 million), an increase of 39% from RMB10,541.5 million in the same quarter of 2022.

DGAP-News: Anne Frank Fonds Basel protects copyrights to works by Anne Frank

Retrieved on: 
Tuesday, February 1, 2022
Anne Frank, KNAW, AFF, Racism, Royal Netherlands Academy of Arts and Sciences, VPN, AFS, Huygens Institute for the History of the Netherlands, Education, Geo-blocking, Diary, Online gambling

Works by Anne Frank have been uploaded onto a Belgian website, which is run by a letterbox company and uses geo-blocking.

Key Points: 
  • Works by Anne Frank have been uploaded onto a Belgian website, which is run by a letterbox company and uses geo-blocking.
  • The Anne Frank Fonds Basel (AFF) instigated a lawsuit against the letterbox company and against the Anne Frank Stichting and KNAW, as this covert bypassing of the protected copyright meant that the works of Anne Frank were also easily accessible in the Netherlands.
  • We will defend copyrights and take the appropriate measures in order to create legal certainty for the Anne Frank Fonds Basel, the publishing houses and its readers."
  • As the only organisation established by Otto Frank, the Anne Frank Fonds (AFF) was founded in 1963 and represents the Frank family.

Aviceda Therapeutics Announces Additional World-Class Members to its Scientific Advisory Board

Retrieved on: 
Monday, September 20, 2021
Technology, Research, Infectious Diseases, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Therapy, VU University Medical Center, JAK3, List of pathologists, KNAW, Dendrite, ERC, Cell, Royal Netherlands Academy of Arts and Sciences, Harvard Medical School, SCID, Aviceda, Inflammation, Pathology, Coronavirus Scientific Advisory Board (Turkey), Cell biology, IP, Immune system, Cancer research, Science, Amgen, JEM, HIV, COO, GA, UCLA, FIH, CSO, Molecular biology, Ghost, DNA repair, DNA, Geographic atrophy, Government, Autosome, Cancer Research UK, Doctor of Philosophy, College, Government of Northern Ireland, Society, Dendritic cell, College of American Pathologists, DNAR, II, NWO, Cancer, CLIA, Patient, Biomarker, Biology, CLEP, McClay, NIH, PNAS, Pharmaceutical industry, Vaccine, Medicine

Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.

Key Points: 
  • Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.
  • The new additional Aviceda Scientific Advisory Board members includes:
    Aviceda is honored and privileged to add new world-class scientists and renowned researchers to join our efforts in developing the next generation of glyco-immune therapeutics for the treatment of immune-dysfunction conditions, said Mohamed A. Genead, MD, Co-Founder & President of Aviceda Therapeutics.
  • She published more than 280 scientific papers in well recognized journals (Cell, Nature, Nature Immunology, PNAS, and JEM) and supervised 29 PhD students.
  • The Aviceda team is already building on the foundational work in the emerging field of glycobiology to develop potential therapeutics and interventional strategies.

STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services

Retrieved on: 
Wednesday, August 18, 2021
Medical Supplies, Health, Infectious Diseases, Stem Cells, Research, Science, Biotechnology, Toxicology, Therapy, Royal Netherlands Academy of Arts and Sciences, Regenerative medicine, Leadership, Science, Research, Drug discovery, B cell, Georgetown University Medical Center, Health, Adult, KNAW, HUB, Partnership, Stemcell Technologies, CEO, Organoid, Organization, Toxicity, University Medical Center Utrecht, Drug development, Pharmaceutical industry

STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use of tissue-derived organoidsincluding lung, intestinal, and liver organoidsfor use in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL.

Key Points: 
  • STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use of tissue-derived organoidsincluding lung, intestinal, and liver organoidsfor use in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL.
  • HUB Organoids represent a patient-specific way of assessing the efficacy and toxicity of drugs during preclinical screening.
  • STEMCELL has already demonstrated thought leadership in the Organoid Technology field; therefore, we believe that expanding the scope of our partnership to include services will benefit the research and drug development community worldwide.
  • Hubrecht Organoid Technology (HUB) was founded by the Hubrecht Institute, the University Medical Center Utrecht, and the Royal Netherlands Academy of Arts and Sciences (KNAW) to refine organoid development and foster organoid adoption globally.